Why did TRP.AX stock drop so sharply pre market?

The sharp pre-market drop to A$0.20 was driven by heavy volume (936,143) and sentiment-sensitive selling in a low market-cap biotech. Key triggers are funding concerns, trial uncertainty, or a large seller; confirm with company notices and block-trade reports.

What is Meyka AI's view on TRP.AX stock value?

Meyka AI rates TRP.AX **61.25/100** (Grade B, HOLD). The model values the stock at A$0.32 over 12 months, implying ~61.33% upside from A$0.20, subject to clinical and funding risks. This is a model projection, not a guarantee.

When is the next catalyst for Tissue Repair Ltd (TRP.AX)?

An earnings announcement is scheduled for 2026-02-19. Expect cash burn, trial updates and guidance items to act as primary catalysts. Any clinical readouts or financing notices will also move the stock materially.

What short-term price targets should traders use for TRP.AX stock?

Short-term targets from our analysis: conservative recovery to A$0.30, upside to A$0.41 on positive news, and downside support near A$0.17. Use tight stops because of high volatility and thin liquidity.

AU Stocks

TRP.AX Tissue Repair (ASX) -35% to A$0.20 pre market 03 Feb 2026: what next

ByDanny Kontos February 2, 2026February 2, 2026

Pre-market the TRP.AX stock plunged 35.48%, trading at A$0.20 on very heavy volume of 936,143 shares as investors sold into a sharp move. The drop follows a gap down from a previous close of A$0.31 and pushed the price near the year low of A$0.17. In this pre market top losers report we examine why Tissue Repair Ltd (TRP.AX, ASX, Australia) fell, what the financials say, and where short-term price action and analyst models point next.